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Recombinant human interferon alpha increases Qestrogen receptor
expression in human breast cancer cells (ZR-75-1) and sensitises them to
the anti-proliferative effects of tamoxifen
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Summary Exposure of ZR-75-1 human breast cancer cells for 48h to human recombinant interferon alpha
(IFNa) resulted in increased expression of oestrogen receptors as measured in a whole cell binding assay. This
effect was inversely proportional to dose being significant following treatment with 10-1OOIUIFNml-l and
was only observed at a low initial cell plating density. The extent of the increase in oestrogen receptor levels
ranged from 1.2- to 7.2-fold following treatment with 1OIUIFNml-'. No increase in progesterone receptor
expression was observed under the same experimental conditions. Concentrations of IFN which increased
oestrogen receptor levels had no effect on cell proliferation. IFN (500 IU ml-1) inhibited cell proliferation and
the combination of this treatment with tamoxifen (2piM) had a greater anti-proliferative effect than either drug
alone although there was no evidence of synergism. However, a 5-day pretreatment of cells with IFN
(10IUml-1) markedly sensitised them to the growth-inhibiting effect of a subsequent 6-day exposure to
tamoxifen.
Anti-oestrogen therapy plays an increasingly important role
in the management of patients with breast carcinoma.
Although the mechanism of action of anti-oestrogens such as
tamoxifen is incompletely understood, there is considerable
evidence that the presence of a functional oestrogen receptor
(ER) in the target tissue is important for the activity of such
drugs in vitro, (Lippman et al., 1976) and in the clinic (Rose
et al., 1985).
In contrast to the proven efficacy of tamoxifen, clinical
trials designed to assess the activity of human recombinant
interferon, (IFN) towards breast cancer have yielded
disappointing results (Sherwin et al., 1983; Nethersell et al.,
1984). Since many of the actions of the IFNs appear to
involve enhanced expression of cellular differentiated
functions (Taylor-Papadimitriou, 1985), we considered the
possibility that ER expression by human breast cancer might
be enhanced by prior exposure of cells to IFN. Two recent
studies have lent some support to this proposal. IFNax was
reported to increase assayable ER when added directly to
breast or uterine cell homogenates, (Dimitrov et al., 1984),
and increased ER and progesterone receptors (PGR) were
detected in skin metastases in a small number of patients
who had received fibroblast IFN for the treatment of
advanced breast cancer (Pouillart et al., 1982).
Confirmation of these data would further suggest that
prior exposure of breast cancer cells to IFN might increase
their sensitivity to tamoxifen. Such a drug combination
would be attractive in the clinical setting given the relative
lack of toxicity of the agents. Marth et al., (1985) failed to
demonstrate any effect of IFNa 2 or IFNy on ER expression
by MCF-7 or BT-20 human breast cancer cell lines whilst
Sica et al., (1986) in a study reported simultaneously with
our own preliminary data (van den Berg et al., 1986),
demonstrated enhanced ER and PGR expression in a subline
of MCF-7 cells following IFNf treatment.
In this paper we have extended our earlier observations
and report that IFNac 2 increases ER but not PGR
expression in the ZR-75-1 human breast cancer cell line and
that the effect on detectable ER is inversely proportional to
dose and dependent on cell plating density. We have also
investigated the consequences of IFN induced enhanced ER
expression on the sensitivity of cells to the anti-proliferative
effects of tamoxifen.
Materials and methods
Cells and culture conditions
The ZR-75-1 human breast cancer line was obtained from
Flow Laboratories (Irvine, Scotland) and its human and
mammary origin has been described previously (Lippman et
al., 1977). Cells were maintained routinely in RPMI 1640
medium supplemented with 5% foetal calf serum,
100IUml-I penicillin and 100,ugml-l streptomycin and
grown in an air: CO2 atmosphere, (95:5 v/v), at 37°C.
Steroid hormone receptor assays
ER and PGR expression were determined using a whole cell
binding assay at 37°C similar to that described by Olea-
Serrano et al. (1985). Cells, (10,000-200,000) were plated
into 24 places multi-well dishes (Flow Laboratories, Irvine,
Scotland) and allowed to attach for 24h. Medium was then
replaced with medium containing 1% charcoal-stripped
serum with or without the addition of 10-1000IUml-1
human recombinant IFNoa 2 arg, (kindly supplied by Bender
& Co, Vienna, Austria). Receptor assays were performed
48 h later. The medium was removed and oestrogen or
progesterone binding assessed using either a single
concentration of ligand (I nM) or a range of concentrations
for determination of maximal binding capacity (Bmax) and
dissociation constant (Kd). Oestrogen (E2) binding was
measured using (2, 4, 6, 7, 16, 17-3-H)E2, (sp. act.
140 Cimmol- 1, Amersham International plc) as the
radioactive ligand (0.25-3.5nM) in the absence or presence
of a 200-fold excess of diethylstilbestrol. Progesterone
binding was determined by incubating cells with (3-H) ORG
2058, (sp. act. 45Cimmol- 1, Amersham International plc) at
a concentration range of 0.2-2nM in the absence or presence
of a 200-fold excess of unlabelled ligand. Cells were exposed
to the radioactive ligands for 1 h, the medium was then
removed and the monolayers washed twice with ice cold PBS
prior to extracting radioactivity with ethanol (0.8ml).
Radioactivity was determined by liquid scintillation counting
and Bmax and Kd determined after linearisation of the data
by the methods of Scatchard (1949) or Woolf (Keightley &
Cressie, 1980). Lines were fitted by linear regression analysis
and standard deviations associated with the derived
parameters estimated, (Davies & Goldsmith 1972).
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C'ompetition binding assays
The ability of IFN or tamoxifen to displace 3-H E2 from its
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binding sites was determined by incubating cells cultured as
described above in the presence of 1nM 3-H E2 together
with IFN (10-1000 lUml-1) or tamoxifen (10-8-10-5M) for
1 h.
Inhibition ofcell population growth
The ability of IFN, tamoxifen or a combination of the two
agents to inhibit the growth of ZR-75-1 cells was determined
under the same conditions as used for receptor assays. Cells
were initially plated at 50,000 cells/well and exposed to each
drug singly or in combination continually for a 6-day period.
In a separate group of experiments cells (10,000/well) were
pre-exposed to IFN, (10IUml- 1), for 5 days and then
exposed to tamoxifen for a further 6 days. Cell number in
drug-treated groups was expressed as a percentage of control
cell number at day 6.
Results
Figure 1 shows the effect of a 2-day exposure to IFN on the
binding of E2 (1 nM) to ZR-75-1 cells plated at two different
cell densities. IFN had no significant effect on E2 binding to
cells plated at a density of 200,000/well. However, when cells
were initially plated at a density of 50,000/well prior
exposure to IFN resulted in an increase in specific binding of
E2 which was inversely proportional to the dose of IFN.
This increase was significant following treatment with 100,
50 and 10 IU IFNml - and was predominantly the result of
an increase in total binding. In this experiment it was also
noted that specific E2 binding in control cells, in comparison
with that observed at the higher plating density, was lower
than could be accounted for simply by the reduction in cell
number. Figure 2 shows a Woolf plot obtained following
exposure of control and IFN, (10IUml-1), treated cells to a
range of 3-H E2 concentrations. IFN treatment resulted in a
more than 2-fold increase in Bmax. In 3 separate
experiments this effect of IFN was confirmed although
expression of ER in control cells showed considerable
variability (Table I). This variability was not apparent when
cells were initially plated at 200,000/well (Bmax 215 +24
fmol mg- 1 protein, mean+s.d. of 5 experiments). In all cases
there was a small decrease in the affinity of E2 for its
receptor in IFN treated cells, but this effect did not reach
significance. Similar increases in ER expression were seen if
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Figure 1 The effects of IFN on the binding of 3-H E2 to ZR-
75-1 cells. (a) Cells plated at 200,000/well; (b) Cells plated at
50,000 cells/well. Total binding El; Non-specific binding D;
Specific binding *. Error bars represent s.d. of triplicate
measurements. *P<0.01 Student's t-test.
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Figure 2 Woolf plot of H-E2 specific binding to ZR-75-1 cells.
Cells were initially plated at 50,000/well. 0 Control; x 48h. pre-
treatment with IFN (I0IUml-1).
Table I The effect of a 48h exposure to IFNa
(0lIUml-1), on ER expression in ZR-75-1 cells.
Results are expressed as means + s.d. (triplicate
measurements) of4 separate experiments.
Bmax (fmolmg-1 protein) Kd(nM)
-IFN +IFN -IFN +IFN
36+ 12 262+8 0.34+0.15 0.49+0.12
83+ 17 178+29 0.2+0.15 0.5+0.1
113+6 193+26 0.5+0.1 0.8+0.2
151+8 180+11 0.4+0.1 0.5+0.1
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Figure 3 The ability of IFN, (0), or tamoxifen, (0), to inhibit
binding of 3-H E2, (lnM), to ZR-75-1 cells. Cells were plated at
50,000/well.
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Figure 4 The ability of IFN and tamoxifen, alone or in
combination, to inhibit proliferation of ZR-75-1 cells during a 6-
day period of treatment. Initial cell no. was 50,000/well. Error
bars represent s.d. of triplicate measurements.
cells were plated at 10,000/well and exposed to IFN
(10IUml-1) for 4 or 5 days (data not shown). E2 binding to
cells was not increased if IFN was included in the 1 h
binding assay (Figure 3). Indeed, there was a small decrease
in E2 binding in cells simultaneously exposed to high
concentrations of IFN. However, IFN competed with E2
poorly for E2 binding sites compared to tamoxifen.
PGR expression, (148 +28fmolmg-1 protein) was
unaffected by a 48h exposure to 10IUIFNml-1. Oestradiol
treatment (10-9M), resulted in a marked elevation of
detectable PGR (Bmax 355 + 12 fmol mg - I protein). Figure 4
shows that 10 IU IFN ml-1, which markedly elevated ER
expression, had no significant effect on the proliferation of
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Figure 5 The effect of a five day exposure of ZR-75-1 cells to
IFN, (10 IU ml-1), on the anti-proliferative effect of a
subsequent 6-day treatment with tamoxifen. Initial cell no. was
10,000/well. Error bars represent s.d. of triplicate measurements.
ZR-75-1 cells over a 6-day period. Simultaneous exposure of
cells to IFN (0lIUml-1), and tamoxifen (2pM) led to a
small increase in anti-proliferative effect compared to
tamoxifen alone but this was not significant. Cell
proliferation was inhibited in cells continually exposed to
500IUml-1 IFN and the combination of this concentration
of IFN and 2pM tamoxifen was more growth inhibitory than
either drug alone but again there was no evidence of
synergism. Sensitisation of cells to the anti-proliferative
effects of tamoxifen could be achieved if they were exposed
to IFN (10IUml-1) for 5 days prior to anti-oestrogen
treatment (Figure 5). IFN alone again had no significant
effect on cell proliferation whilst IFN pre-treatment reduced
the cell number (as a percentage of control at day 6) of 2pM
tamoxifen treated cells from 81+5% to 59+6%, (P<0.01).
Discussion
We have demonstrated that IFNa increases ER expression in
the ZR-75-1 human breast cancer cell line. Similar results
were reported for the activity of the IFN,B subtype towards
an E2 supersensitive variant of the MCF-7 breast cancer cell
line (Sica et al, 1986). Our data further suggest that this
effect of IFNa is only observed at low doses in the ZR-75-1
line and is dependent on a low initial cell plating density. In
this respect our data are in agreement with those of Marth et
al. (1985) who also failed to demonstrate any effect of IFNa
(500 IU ml-1) on ER expression in this cell line or in the ER
negative line BT-20. The reasons for the constraints on IFN
effects on ER we have observed are presently unclear,
although it is apparent that the anti-proliferative effects of
IFNx are dissociated from its effect on ER expression
(Figures 1 and 4). ER expression in human breast cancer
cells has been reported to be dependent on cell proliferation
rate, with lower receptor levels being associated with rapidly
dividing cells (Jakesz et al., 1984). Under the experimental
conditions described cells plated at 50,000/well grow
exponentially whilst at 200,000/well virtual confluence is
reached. It is possible, therefore, that IFN prevents this
'down regulation' of ER accompanying rapid cell
proliferation. However, although control levels in cells plated
at the lower density were occasionally low, considerable
variability was observed although the effects of IFN were
consistent (Table I). Our data do not support the
proposition that IFN causes an apparent increase in E2
binding through the formation of an IFN-ER-E2 complex
(Dimitrov et al., 1984) since E2 binding was unchanged
when the assay was performed in the presence of low
concentrations of IFN (Figure 3). However, since our data
were obtained using a whole cell binding assay, it is probable
that IFN would not gain access to intracellularily located
ER.
We are currently investigating the effect of IFN on ER
expression in the presence of cycloheximide and preliminary
data indicate that ER levels are low in both control anl IFN
treated cells, suggesting that intact protein synth sis is
required for IFN induced enhanced ER expression.
The proposal that increased ER expression followinj IFN
treatment represents a true increase in receptor numbers
receives support from the observation that prior exposure to
IFN increases the anti-proliferative effects of tamoxifen in
this cell line (Figure 5). The schedule of treatment is clearly
critical since no synergism was apparent when IFN and
tamoxifen were administered simultaneously (Figure 4).
We have been unable to demonstrate an increase in PGR
levels following IFN treatment (Sica et al., 1986).
Nevertheless our results suggest that a combination of low
doses of IFN prior to tamoxifen therapy may have potential
as an in vivo treatment regime, possibly as a result of IFN
induced enhanced ER levels in target cells. Such a drug
combination might be expected to be well tolerated.
However, we are aware that the present study is limited by
the use of a single breast cancer cell line. It will be important
to determine whether other mechanisms are involved in the
synergistic activity of IFN and tamoxifen. Since breast
cancer is a heterogeneous disease with respect to ER
expression it will be equally important to determine whether
IFN is able to induce ER synthesis in ER negative tumour
cells.
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